The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
 
Erica Michelle Stringer-Reasor
Honoraria - Breast Cancer Index; Lilly; Mylan
Consulting or Advisory Role - Immunomedics; Lilly; Novartis
Speakers' Bureau - Lilly
Research Funding - Susan G. Komen for the Cure; V Foundation
Travel, Accommodations, Expenses - Cascadian Therapeutics; Lilly
(OPTIONAL) Uncompensated Relationships - Genentech
 
Yufeng Li
No Relationships to Disclose
 
Felicia Witherspoon
No Relationships to Disclose
 
Jennifer M. Specht
Honoraria - Daiichi Sankyo; Genomic Health; Nektar
Consulting or Advisory Role - Daiichi Sankyo; Genomic Health; Nektar
Research Funding - Cascadian Therapeutics (Inst); Genentech (Inst); Merck (Inst); Minerva Biotechnologies (Inst); Myriad Pharmaceuticals (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Nektar
 
Jesus Del Santo Anampa Mesias
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; Immunomedics; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Elizabeth Claire Dees
Consulting or Advisory Role - G1 Therapeutics; Novartis (I); Strata Oncology
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - G1 Therapeutics
 
Antonio C. Wolff
Consulting or Advisory Role - Ionis Pharmaceuticals
Research Funding - Biomarin (Inst); Celldex (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Leadership - AMAG Pharmaceuticals (I); Freeline Therapeutics (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I); Freeline Therapeutics (I); vertex (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Ionis Pharmaceuticals; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Nancy U Lin
No Relationships to Disclose
 
Mothaffar F. Rimawi
Consulting or Advisory Role - Daiichi Sankyo; Genentech; Macrogenics; Seagen
Research Funding - Pfizer (Inst)
 
Eddy Shih-Hsin Yang
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Lilly; Strata Oncology
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst); Puma Biotechnology (Inst)